Compare MATW & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | RIGL |
|---|---|---|
| Founded | 1850 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 628.4M |
| IPO Year | 1995 | 2000 |
| Metric | MATW | RIGL |
|---|---|---|
| Price | $25.45 | $27.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | 185.5K | ★ 287.1K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.02% | N/A |
| EPS Growth | 59.07 | ★ 1867.68 |
| EPS | 1.39 | ★ 19.48 |
| Revenue | ★ $1,795,737,000.00 | $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | $18.26 | ★ $1.41 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $18.50 | $15.50 |
| 52 Week High | $29.11 | $52.24 |
| Indicator | MATW | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 43.51 |
| Support Level | $23.70 | $26.38 |
| Resistance Level | $25.67 | $30.59 |
| Average True Range (ATR) | 0.75 | 0.93 |
| MACD | 0.12 | 0.48 |
| Stochastic Oscillator | 64.68 | 79.35 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.